Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

Evaluate the effect of vemurafenib on BRAF V600E mutant papillary craniopharyngioma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPC-17013601

Enrollment

Unknown

Registered

2017-11-29

Start date

2018-01-01

Completion date

Unknown

Last updated

2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Craniopharyngioma

Interventions

Case series:vemurafenib

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients with craniopharyngioma recurrence after sugery; (2) Papillary craniopharyngioma with BRAFv600e mutation; (3) Compared to the last CT orMRI,the leision increased more than 0.4cm; (4) Aged 18-70 years male and female; (5) KPS>60 and Barthel>80; (6) Patients volunteered to join the study and signed the informed consent (ICF).

Exclusion criteria

Exclusion criteria: (1) Patients with increased intracranial pressure; (2) Patients with receiving radiation in 6months; (3) Unwilling to sign the informed cnonsent; (4) Patients with participate in other clinical trials; (5) Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Tumor response rate;Progression free survival;	—

Secondary

Measure	Time frame
Side effect;Quality of Life;	—

Countries

China

Contacts

Public ContactXin Yu

Navy General Hospital of PLA

yuxin37@sina.cn+86 18600310210

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026